What is Amneal Pharmaceuticals, Inc.'s revenue?

Amneal Pharmaceuticals, Inc. (AMRX) generated $3.0B in revenue over the trailing twelve months, up 7.6% year over year.

Is Amneal Pharmaceuticals, Inc. profitable?

Amneal Pharmaceuticals, Inc. reported $122.1M in net income over the trailing twelve months, a 4.0% net margin.

What are Amneal Pharmaceuticals, Inc.'s profit margins?

Gross margin is 38.7% and operating margin is 14.3%, with a 4.0% net margin.

What is Amneal Pharmaceuticals, Inc.'s earnings per share?

Amneal Pharmaceuticals, Inc.'s diluted EPS over the trailing twelve months is $0.38.

Where does Amneal Pharmaceuticals, Inc.'s income statement data come from?

Every line is extracted from Amneal Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Amneal Pharmaceuticals, Inc. AMRX Income Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY QoQ

Simplified Detailed

	Q1 '26	Q4 '25	Q3 '25	Q2 '25	Q1 '25
Total revenue	$722.52M-11.3%	$814.32M+3.8%	$784.51M+8.3%	$724.51M+4.2%	$695.42M-4.8%
Total cost of revenue	$402.41M-22.2%	$517.13M+1.3%	$510.54M+16.5%	$438.26M-0.3%	$439.53M-6.0%
Gross profit	$320.11M+7.7%	$297.19M+8.5%	$273.97M-4.3%	$286.25M+11.9%	$255.89M-2.7%
Gross margin	44.3%+7.8pp	36.5%+1.6pp	34.9%-4.6pp	39.5%+2.7pp	36.8%+0.8pp
Research and development	$38.38M+10.2%	$34.82M-45.0%	$63.35M+32.1%	$47.96M+19.8%	$40.04M-26.2%
Selling, general and administrative	$138.86M-5.2%	$146.46M+6.3%	$137.82M+10.9%	$124.27M+5.1%	$118.29M-8.1%
Acquisition and integration costs	$5.15M—	——	——	——	$0—
Other operating expenses	$6.94M+694,000%	$1K-99.1%	$117K—	$0-100%	$5.12M—
Operating income	$141.77M+26.5%	$112.03M+59.3%	$70.34M-36.8%	$111.37M+11.0%	$100.35M+32.4%
Operating margin	19.6%+5.9pp	13.8%+4.8pp	9%-6.4pp	15.4%+0.9pp	14.4%+4.1pp
Interest expense	-$53.36M+5.1%	-$56.24M+10.5%	-$62.81M+3.5%	-$65.1M-14.3%	-$56.94M+7.7%
Other income (expense), net	-$61.6M-8.4%	-$56.8M+24.8%	-$75.57M-26.7%	-$59.66M+5.1%	-$62.86M+31.0%
Gain (loss) on extinguishment of debt	-$3.51M—	——	-$31.37M—	——	$0—
Income before income taxes	$80.18M+45.2%	$55.24M+1,158%	-$5.22M-110%	$51.71M+37.9%	$37.49M+345%
Income tax expense	$2.18M-61.6%	$5.66M+124%	-$23.36M-245%	$16.1M+25.1%	$12.87M+137%
Net income	$62.26M+77.5%	$35.08M+1,381%	$2.37M-89.4%	$22.42M+83.8%	$12.2M+139%
Net margin	8.6%+4.3pp	4.3%+4.0pp	0.3%-2.8pp	3.1%+1.3pp	1.8%+6.0pp
Diluted earnings per share	$0.19+72.7%	$0.11+1,000%	$0.01-85.7%	$0.07+75.0%	$0.04+140%
Basic earnings per share	$0.20+81.8%	$0.11+1,000%	$0.01-85.7%	$0.07+75.0%	$0.04+140%
Weighted-average shares, diluted	328.9M+1.3%	324.8M0.0%	324.8M+0.7%	322.4M-0.5%	324M+4.8%
Weighted-average shares, basic	316M+0.8%	313.4M-0.3%	314.2M+0.1%	313.7M+0.9%	311.1M+0.7%
Legal contingency and settlement	-$694K—	$0—	$0-100%	$390K—	$0+100%
Decrease (increase) in tax receivable agreement liability	$2.33M+119%	-$12.29M-159%	$20.81M+571%	-$4.42M+58.6%	-$10.69M+55.4%
Interest Income (Expense), Nonoperating	-$53.36M+5.1%	-$56.24M+10.5%	-$62.81M+3.5%	-$65.1M-14.3%	-$56.94M+7.7%
Gain (Loss), Foreign Currency Transaction, before Tax	-$7.8M—	——	-$3.43M-142%	$8.26M+94.4%	$4.25M+155%
Intellectual property legal development expenses	$1.54M+9.3%	$1.41M-42.1%	$2.44M+20.8%	$2.02M+14.1%	$1.77M-4.6%
Other income, net (Note 6)	$742K-94.4%	$13.17M+966%	$1.24M-23.0%	$1.6M+210%	$518K-76.2%
Other income, net	$6.94M+694,000%	$1K-99.1%	$117K—	$0-100%	$5.12M—
Revenue From Contract With Customer Excluding Assessed Tax	$722.52M-11.3%	$814.32M+3.8%	$784.51M+8.3%	$724.51M+4.2%	$695.42M-4.8%
EBIT	$141.77M+26.5%	$112.03M+59.3%	$70.34M-36.8%	$111.37M+11.0%	$100.35M+32.4%
EBIT	$141.77M+26.5%	$112.03M+59.3%	$70.34M-36.8%	$111.37M+11.0%	$100.35M+32.4%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Ask your AI about Amneal Pharmaceuticals, Inc..

Connect your AI assistant and get a quick read on the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Amneal Pharmaceuticals, Inc.'s revenue?: Amneal Pharmaceuticals, Inc. (AMRX) generated $3.0B in revenue over the trailing twelve months, up 7.6% year over year.
Is Amneal Pharmaceuticals, Inc. profitable?: Amneal Pharmaceuticals, Inc. reported $122.1M in net income over the trailing twelve months, a 4.0% net margin.
What are Amneal Pharmaceuticals, Inc.'s profit margins?: Gross margin is 38.7% and operating margin is 14.3%, with a 4.0% net margin.
What is Amneal Pharmaceuticals, Inc.'s earnings per share?: Amneal Pharmaceuticals, Inc.'s diluted EPS over the trailing twelve months is $0.38.
Where does Amneal Pharmaceuticals, Inc.'s income statement data come from?: Every line is extracted from Amneal Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.